Effect of COVID-19 Pandemic-Related Delays in Chemoembolization on the Survival of Patients with Hepatocellular Carcinoma

Table 4

Treatment response analysis at 1 month of prelockdown versus lockdown.

Treatment response	Prelockdown group (n = 87)	Lockdown group (n = 58)	value
mRECIST at 1 month			0.908
CR	18 (20.7)	14 (24.1)
PR	38 (43.7)	24 (41.4)
SD	10 (11.5)	5 (8.6)
PD	21 (24.1)	15 (25.9)
BCLC stage migration	3 (3.4)	4 (6.9)	0.438

Data are presented as n (%). mRECIST, modified response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; BCLC, Barcelona Clinic Liver Cancer.